PLIANT THERAPEUTICS, INC. (PLRX) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US7291391057

Price
0.70 USD
Market cap
42.77 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

PLIANT THERAPEUTICS, INC. financials

Fiscal year2025
Revenue0.00 USD
Operating income-156.37 m USD
EBIT-146.79 m USD
Net income-149.34 m USD
Diluted EPS – continuing operations-2.43 USD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About PLIANT THERAPEUTICS, INC.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.